Cannabix and Omega Expand Breath Testing to Multi-Drug Panel for Recent-Use Detection — Cannabix Technologies Inc.

Event summary

Cannabix and Omega have developed a breath-based drug-testing panel that detects multiple drug classes, modeled after the DOT urine test panel.
The panel includes amphetamines, cocaine, marijuana, opiates, and PCP, expanding beyond cannabinoids to support recent-use detection in safety-sensitive environments.
Omega’s laboratory-based method uses mass spectrometry for confirmation, with Cannabix providing the Breath Collection Unit and Cartridge system.
Cannabix has also entered a one-month marketing agreement with Black Swan Solutions for digital marketing services, paying $20,000 plus GST.

The big picture

The expansion of breath testing to a multi-drug panel addresses growing demand for time-relevant drug detection, particularly as marijuana legalization accelerates. This development positions Cannabix and Omega at the forefront of a shift toward non-invasive, recent-use testing in workplace and forensic settings. The partnership leverages Omega’s toxicology expertise and Cannabix’s hardware innovation to challenge traditional drug-testing matrices like urine and hair analysis.

What we're watching

Market Adoption: Whether employers and safety-sensitive programs will widely adopt breath-based multi-drug testing over traditional methods.
Regulatory Acceptance: The pace at which regulatory bodies endorse breath testing as a legally defensible standard for recent-use detection.
Competitive Positioning: How Cannabix and Omega differentiate their solution in a market with evolving drug-testing technologies.